Last reviewed · How we verify
pembrolizumab and lenvatinib — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
pembrolizumab and lenvatinib (pembrolizumab and lenvatinib) — Prof. Dr. Remi A. Nout.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| pembrolizumab and lenvatinib TARGET | pembrolizumab and lenvatinib | Prof. Dr. Remi A. Nout | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- pembrolizumab and lenvatinib CI watch — RSS
- pembrolizumab and lenvatinib CI watch — Atom
- pembrolizumab and lenvatinib CI watch — JSON
- pembrolizumab and lenvatinib alone — RSS
Cite this brief
Drug Landscape (2026). pembrolizumab and lenvatinib — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-and-lenvatinib. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab